[go: up one dir, main page]

NO975234D0 - Fremgangsmåte for behandling av maniske og bipolare forstyrrelser - Google Patents

Fremgangsmåte for behandling av maniske og bipolare forstyrrelser

Info

Publication number
NO975234D0
NO975234D0 NO975234A NO975234A NO975234D0 NO 975234 D0 NO975234 D0 NO 975234D0 NO 975234 A NO975234 A NO 975234A NO 975234 A NO975234 A NO 975234A NO 975234 D0 NO975234 D0 NO 975234D0
Authority
NO
Norway
Prior art keywords
bipolar disorders
treating manic
treatment
manic
treating
Prior art date
Application number
NO975234A
Other languages
English (en)
Other versions
NO315967B1 (no
NO975234L (no
Inventor
Atul Chandra Pande
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of NO975234D0 publication Critical patent/NO975234D0/no
Publication of NO975234L publication Critical patent/NO975234L/no
Publication of NO315967B1 publication Critical patent/NO315967B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Beans For Foods Or Fodder (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Indole Compounds (AREA)
  • Saccharide Compounds (AREA)
NO19975234A 1995-05-15 1997-11-14 Anvendelse av gabapentin og dets derivater i behandling av mani og biopolarforstyrrelse NO315967B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/440,570 US5510381A (en) 1995-05-15 1995-05-15 Method of treatment of mania and bipolar disorder
PCT/US1996/005898 WO1996036328A1 (en) 1995-05-15 1996-04-26 A method of treatment of mania and bipolar disorder

Publications (3)

Publication Number Publication Date
NO975234D0 true NO975234D0 (no) 1997-11-14
NO975234L NO975234L (no) 1997-11-14
NO315967B1 NO315967B1 (no) 2003-11-24

Family

ID=23749281

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19975234A NO315967B1 (no) 1995-05-15 1997-11-14 Anvendelse av gabapentin og dets derivater i behandling av mani og biopolarforstyrrelse

Country Status (19)

Country Link
US (1) US5510381A (no)
EP (1) EP0825857B1 (no)
JP (1) JPH11505244A (no)
AT (1) ATE218857T1 (no)
AU (1) AU702435B2 (no)
CA (1) CA2215923C (no)
CZ (1) CZ288072B6 (no)
DE (1) DE69621799T2 (no)
DK (1) DK0825857T3 (no)
EE (1) EE03420B1 (no)
ES (1) ES2177783T3 (no)
GE (1) GEP20002014B (no)
HU (1) HUP9802087A3 (no)
NO (1) NO315967B1 (no)
NZ (1) NZ307366A (no)
PT (1) PT825857E (no)
SK (1) SK281982B6 (no)
WO (1) WO1996036328A1 (no)
ZA (1) ZA963826B (no)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6372792B1 (en) 1996-04-26 2002-04-16 Guy Chouinard Method for treating anxiety, anxiety disorders and insomnia
IL126999A (en) 1996-07-24 2002-03-10 Warner Lambert Co Pharmaceutical preparations containing isobutylgaba and its history for use in the treatment of pain
AU9318398A (en) 1997-10-07 1999-04-27 Warner-Lambert Company Process for preparing a cyclic amino acid anticonvulsant compound
US6635673B1 (en) 1997-10-27 2003-10-21 Warner-Lambert Company Cyclic amino acids and derivatives thereof useful as pharmaceutical agents
WO1999059572A1 (en) * 1998-05-15 1999-11-25 Warner-Lambert Company Gamma-aminobutyric acid derivatives containing, solid compositions and process for preparing the same
WO1999059573A1 (en) 1998-05-15 1999-11-25 Warner-Lambert Company Stabilized pharmaceutical preparations of gamma-aminobutyric acid derivatives and process for preparing the same
AU757445B2 (en) 1998-05-26 2003-02-20 Warner-Lambert Company Conformationally constrained amino acid compounds having affinity for the alpha2delta subunit of a calcium channel
BR9911887A (pt) * 1998-07-09 2001-03-27 Warner Lambert Co Método para o tratamento da insÈnia
DK1121114T3 (da) * 1998-10-16 2007-04-10 Warner Lambert Co Anvendelse af GABA-analoger til fremstilling af et medikament til behandling af mani og bipolære lidelser
EP1187832B1 (en) * 1999-06-02 2002-11-20 Warner-Lambert Company Amino heterocycles useful as pharmaceutical agents
AP2002002501A0 (en) * 1999-10-07 2002-06-30 Warner Lambert Co Synergistic combinations of an NK1 receptor antagonist and a gaba structural analog.
EP1294364A4 (en) * 2000-06-16 2004-06-16 Teva Pharma STABLE GABAPENTINE WITH A PH WITHIN A CONTROLLED AREA
BR0111913A (pt) * 2000-06-26 2004-01-06 Warner Lambert Co Análogos de gabapentina para distúrbios do sono
ITMI20012750A1 (it) 2001-12-21 2003-06-21 Procos Spa Processo per la produzione dell'acido 1-(amminometil)-cicloesil-acetico in forma pura
US20030119908A1 (en) * 2001-12-21 2003-06-26 Zambon Group S.P.A. Stable gabapentin compositions
CA2451267A1 (en) * 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
WO2011151708A1 (en) 2010-06-01 2011-12-08 Rubicon Research Private Limited Gastroretentive dosage forms of gaba analogs
EP2923694B1 (en) 2014-03-27 2018-11-14 Sanovel Ilac Sanayi ve Ticaret A.S. Oral liquid pharmaceutical solution of gabapentin
US11670410B1 (en) * 2022-04-13 2023-06-06 Green Sky Creations LLC Systems and methods to automatically administer a psychoactive substance to an airway of a user based on a detected event or condition

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2460891C2 (de) * 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US4087544A (en) * 1974-12-21 1978-05-02 Warner-Lambert Company Treatment of cranial dysfunctions using novel cyclic amino acids
US4355044A (en) * 1980-12-19 1982-10-19 Bernardo Heller D-Phenylalanine treatment
US5084479A (en) * 1990-01-02 1992-01-28 Warner-Lambert Company Novel methods for treating neurodegenerative diseases
US5086072A (en) * 1990-06-18 1992-02-04 The United States Of America As Represented By The Department Of Health And Human Services Treatment of mood disorders with functional antagonists of the glycine/nmda receptor complex
US5025035A (en) * 1990-10-12 1991-06-18 Warner-Lambert Company Method of treating depression

Also Published As

Publication number Publication date
DE69621799T2 (de) 2003-01-02
HUP9802087A3 (en) 1999-08-30
CZ355897A3 (cs) 1998-02-18
US5510381A (en) 1996-04-23
MX9707269A (es) 1997-11-29
EE03420B1 (et) 2001-06-15
ES2177783T3 (es) 2002-12-16
CA2215923C (en) 2001-10-09
EE9700302A (et) 1998-06-15
NO315967B1 (no) 2003-11-24
DK0825857T3 (da) 2002-09-30
NZ307366A (en) 1999-10-28
SK281982B6 (sk) 2001-09-11
PT825857E (pt) 2002-11-29
ZA963826B (en) 1996-11-21
ATE218857T1 (de) 2002-06-15
NO975234L (no) 1997-11-14
DE69621799D1 (de) 2002-07-18
EP0825857A1 (en) 1998-03-04
EP0825857B1 (en) 2002-06-12
AU702435B2 (en) 1999-02-18
WO1996036328A1 (en) 1996-11-21
AU5668996A (en) 1996-11-29
JPH11505244A (ja) 1999-05-18
HUP9802087A2 (hu) 1998-12-28
CZ288072B6 (cs) 2001-04-11
SK152897A3 (en) 1999-05-07
GEP20002014B (en) 2000-04-10
CA2215923A1 (en) 1996-11-21

Similar Documents

Publication Publication Date Title
NO975234D0 (no) Fremgangsmåte for behandling av maniske og bipolare forstyrrelser
CA2344407A1 (en) Method for the treatment of mania and bipolar disorder
ATE127804T1 (de) Pharmazeutische verbindungen.
DE69722426D1 (de) Isobutylgaba und dessen derivate zur schmerzbehandlung
CA2258895A1 (en) Use of topiramate or derivatives thereof for the manufacture of a medicament for the treatment of manic-depressive bipolar disorders
PL323798A1 (en) Application of derivatives of vitamin d4 in treating skin diseases
UA27870C2 (uk) Фармацевтичний препарат
ATE119770T1 (de) Verwendung von acetyl l-carnitin zur therapeutischen behandlung von coma.
ATE247966T1 (de) Behandlung von motorischen fehlfunktionen
DE69605531D1 (de) Carnitinderivat als Arzneimittel zur Behandlung von Arteriosklerose obliterans
ATE275966T1 (de) Activin stimulator enthaltende pharmazeutische zusammensetzung
YU42298A (sh) Upotreba olanzapina za pripremanje leka korisnog kod akutnog bola
RU94040886A (ru) Применение производных мелатонина для лечения нарушений сна, фармацевтическая композиция
RU94041028A (ru) Применение производных мелатонина для лечения десинхронизационных нарушений, фармацевтическая композиция
NO984197D0 (no) Fremgangsmåte for behandling av autisme
NO953003L (no) Anvendelse av ifenprodil og diastereoisomerer derav for fremstilling av medisinske preparater
NO971453D0 (no) Anvendelse av bradykinin-antagonister for fremstilling av legemidler for behandling av kroniske fibrogenetiske og akutte leversykdommer
BR9801839A (pt) Medicamento analgésico e aplicação de (+) -0-demetiltramadol.
DE60004093D1 (de) Pharmazeutische zusammensetzung welche riluzol und gabapentin enthält zur behandung von motoneuronalen krankheiten
YU40098A (sh) Upotreba olanzapina za dobijanje leka
BG102009A (en) Method for the treatment of manic and two-pole disease
IT1263076B (it) Uso orale e topico della n-acetil-5-metossitriptamina (melatonina) nella terapia della psoriasi volgare.